Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 14.06 NOK 1.01% Market Closed
Market Cap: 718m NOK
Have any thoughts about
Arcticzymes Technologies ASA?
Write Note
Section:
 

Relative Value

The Relative Value of one AZT stock under the Base Case scenario is 28.16 NOK. Compared to the current market price of 14.06 NOK, Arcticzymes Technologies ASA is Undervalued by 50%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZT Relative Value
Base Case
28.16 NOK
Undervaluation 50%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.6
P/S
P/S
Price to Sales
6.6
vs History
92
vs Industry
45
Median 3Y
16.5
Median 5Y
21.9
Industry
7.5
Forward
6.1
More Details
102.5
P/E
P/E
Price to Earnings
102.5
vs History
20
vs Industry
2
Median 3Y
88.6
Median 5Y
77
Industry
21.3
Forward
48
More Details
126.4
P/OCF
P/OCF
Price to OCF
126.4
vs History
4
vs Industry
4
Median 3Y
60.9
Median 5Y
63.1
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
78.3
Median 5Y
73.7
Industry
23.3
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
98
vs Industry
23
Median 3Y
6.8
Median 5Y
12.5
Industry
2.5
More Details
5.1
EV/S
EV/S
Enterprise Value to Sales
5.1
vs History
92
vs Industry
41
Median 3Y
14.8
Median 5Y
21.2
Industry
7.4
Forward
4.7
More Details
5.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.4
vs History
92
vs Industry
41
Median 3Y
15.4
Median 5Y
19.3
Industry
8.8
More Details
123
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
123
vs History
4
vs Industry
2
Median 3Y
68.9
Median 5Y
65.2
Industry
4.2
Forward
182.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
1
Median 3Y
77.9
Median 5Y
69.2
Industry
4
Forward
-182.6
More Details
97.4
EV/OCF
EV/OCF
Enterprise Value to OCF
97.4
vs History
6
vs Industry
4
Median 3Y
55.6
Median 5Y
58.1
Industry
6.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
70.1
Median 5Y
71.8
Industry
3.9
More Details
3.4
EV/IC
EV/IC
Enterprise Value to IC
3.4
vs History
98
vs Industry
20
Median 3Y
22.5
Median 5Y
31.5
Industry
4.6
More Details

Multiples Across Competitors

AZT Competitors Multiples
Arcticzymes Technologies ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Arcticzymes Technologies ASA
OSE:AZT
718.1m NOK 6.6 102.5 123 -371.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 642 728.8 -183 663.2 -223 025.5 -220 480.5
US
Abbvie Inc
NYSE:ABBV
320.2B USD 5.8 63 15.6 24.1
US
Amgen Inc
NASDAQ:AMGN
140.4B USD 4.3 33.2 15.9 30.2
US
Gilead Sciences Inc
NASDAQ:GILD
113.9B USD 4 903.9 10 10
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.9B USD 9.9 -218.7 21.6 22.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 823.1 -465.2 -506.6 -493.1
AU
CSL Ltd
ASX:CSL
137B AUD 5.8 32.2 19.9 24.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.7 17 15.4 17.2
US
Seagen Inc
F:SGT
39.3B EUR 17.6 -53.8 -57.8 -52.2
NL
argenx SE
XBRU:ARGX
36.6B EUR 17.2 -333 -157.8 -102.8
P/S Multiple
Revenue Growth P/S to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average P/S: 3 513 148.1
6.6
13%
0.5
FR
Pharnext SCA
OTC:PNEXF
38 642 728.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
6%
1
US
Amgen Inc
NASDAQ:AMGN
4.3
8%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
4
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
1 823.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.8
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
7%
0.8
US
S
Seagen Inc
F:SGT
17.6
30%
0.6
NL
argenx SE
XBRU:ARGX
17.2
47%
0.4
P/E Multiple
Earnings Growth PEG
NO
Arcticzymes Technologies ASA
OSE:AZT
Average P/E: 192
102.5
37%
2.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -183 663.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
63
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.2
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
903.9
21%
43
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -218.7
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -465.2 N/A N/A
AU
CSL Ltd
ASX:CSL
32.2
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -333 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBITDA: 31.7
123
4%
30.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -223 025.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.6
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
15.9
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -506.6 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -157.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBIT: 21.5
Negative Multiple: -371.8
10%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 480.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.2
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.9
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A N/A

See Also

Summary
AZT intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZT stock valuation using valuation multiples.
Wall Street Estimates
AZT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 214,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.